| Application no. and date | 14718854.4 (espacenet) (Federated) (European Patent Register), 20140314 | | Patent/reg. no. and date | DK/EP 2970250, 20210421 | | Publication date | 20160120 | | Priority no. and date | US 201361791706 P, 20130315 | | EP pub. no. and date |
EP 2970250 20160120 | | Effective date | | | Applicant/owner | Genzyme Corporation, 50 Binney Street
Cambridge, MA 02142, US | | Applicant ref. no. | 1584984 | | Inventor | SIEGEL, Craig, c/o Sanofi U.S.
55 Corporate Drive
Mail Code: 55A-505A
Bridgewater, New Jersey 08807, US,
ZHAO, Jin, c/o Sanofi U.S.
55 Corporate Drive
Mail Code: 55A-505A
Bridgewater, New Jersey 08807, US | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 31/439 (2006.01) , A61P 3/00 (2006.01) , A61P 35/00 (2006.01) , C07D 453/00 (2006.01) | | Title | SALTFORMER AF (S)-QUINUCLIDIN-3-YL-(2-(2-(4-FLUORPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMAT | | Int. application no. | US2014027081 | | Int. publication no. | WO2014152215 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
